389 related articles for article (PubMed ID: 38397040)
1. Pathogenetic Contributions and Therapeutic Implications of Transglutaminase 2 in Neurodegenerative Diseases.
Liu J; Mouradian MM
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397040
[TBL] [Abstract][Full Text] [Related]
2. Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases.
Sengupta U; Kayed R
Prog Neurobiol; 2022 Jul; 214():102270. PubMed ID: 35447272
[TBL] [Abstract][Full Text] [Related]
3. New insight into transglutaminase 2 and link to neurodegenerative diseases.
Min B; Chung KC
BMB Rep; 2018 Jan; 51(1):5-13. PubMed ID: 29187283
[TBL] [Abstract][Full Text] [Related]
4. Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies.
Junn E; Ronchetti RD; Quezado MM; Kim SY; Mouradian MM
Proc Natl Acad Sci U S A; 2003 Feb; 100(4):2047-52. PubMed ID: 12576551
[TBL] [Abstract][Full Text] [Related]
5. Transglutaminase 2 Depletion Attenuates α-Synuclein Mediated Toxicity in Mice.
Zhang J; Grosso Jasutkar H; Yan R; Woo JM; Lee KW; Im JY; Junn E; Iismaa SE; Mouradian MM
Neuroscience; 2020 Aug; 441():58-64. PubMed ID: 32502569
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapeutic Approaches for the Treatment of Neurodegenerative Diseases: Challenges and Outcomes.
Sushma ; Mondal AC
CNS Neurol Disord Drug Targets; 2023; 22(3):404-416. PubMed ID: 34963438
[TBL] [Abstract][Full Text] [Related]
7. Transglutaminase 2 as a therapeutic target for neurological conditions.
Keillor JW; Johnson GVW
Expert Opin Ther Targets; 2021 Sep; 25(9):721-731. PubMed ID: 34607527
[TBL] [Abstract][Full Text] [Related]
8. Transglutaminase 2: biology, relevance to neurodegenerative diseases and therapeutic implications.
Grosso H; Mouradian MM
Pharmacol Ther; 2012 Mar; 133(3):392-410. PubMed ID: 22212614
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.
Valera E; Spencer B; Masliah E
Neurotherapeutics; 2016 Jan; 13(1):179-89. PubMed ID: 26494242
[TBL] [Abstract][Full Text] [Related]
10. Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies.
Bourdenx M; Koulakiotis NS; Sanoudou D; Bezard E; Dehay B; Tsarbopoulos A
Prog Neurobiol; 2017 Aug; 155():171-193. PubMed ID: 26209472
[TBL] [Abstract][Full Text] [Related]
11. Critical role of transglutaminase and other stress proteins during neurodegenerative processes.
Caccamo D; Currò M; Condello S; Ferlazzo N; Ientile R
Amino Acids; 2010 Feb; 38(2):653-8. PubMed ID: 19960212
[TBL] [Abstract][Full Text] [Related]
12. Secondary Protein Aggregates in Neurodegenerative Diseases: Almost the Rule Rather than the Exception.
Moda F; Ciullini A; Dellarole IL; Lombardo A; Campanella N; Bufano G; Cazzaniga FA; Giaccone G
Front Biosci (Landmark Ed); 2023 Oct; 28(10):255. PubMed ID: 37919089
[TBL] [Abstract][Full Text] [Related]
13. Transglutaminase 2 exacerbates α-synuclein toxicity in mice and yeast.
Grosso H; Woo JM; Lee KW; Im JY; Masliah E; Junn E; Mouradian MM
FASEB J; 2014 Oct; 28(10):4280-91. PubMed ID: 24970392
[TBL] [Abstract][Full Text] [Related]
14. Structural basis of the interplay between α-synuclein and Tau in regulating pathological amyloid aggregation.
Lu J; Zhang S; Ma X; Jia C; Liu Z; Huang C; Liu C; Li D
J Biol Chem; 2020 May; 295(21):7470-7480. PubMed ID: 32291284
[TBL] [Abstract][Full Text] [Related]
15. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.
Mollenhauer B; Parnetti L; Rektorova I; Kramberger MG; Pikkarainen M; Schulz-Schaeffer WJ; Aarsland D; Svenningsson P; Farotti L; Verbeek MM; Schlossmacher MG
J Neurochem; 2016 Oct; 139 Suppl 1():290-317. PubMed ID: 26452984
[TBL] [Abstract][Full Text] [Related]
16. Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.
Vaikath NN; Majbour NK; Paleologou KE; Ardah MT; van Dam E; van de Berg WD; Forrest SL; Parkkinen L; Gai WP; Hattori N; Takanashi M; Lee SJ; Mann DM; Imai Y; Halliday GM; Li JY; El-Agnaf OM
Neurobiol Dis; 2015 Jul; 79():81-99. PubMed ID: 25937088
[TBL] [Abstract][Full Text] [Related]
17. Interactions of pathological proteins in neurodegenerative diseases.
Spires-Jones TL; Attems J; Thal DR
Acta Neuropathol; 2017 Aug; 134(2):187-205. PubMed ID: 28401333
[TBL] [Abstract][Full Text] [Related]
18. Prolyl oligopeptidase colocalizes with α-synuclein, β-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson's and Alzheimer's diseases.
Hannula MJ; Myöhänen TT; Tenorio-Laranga J; Männistö PT; Garcia-Horsman JA
Neuroscience; 2013 Jul; 242():140-50. PubMed ID: 23562579
[TBL] [Abstract][Full Text] [Related]
19. α-Synuclein Heteromers in Red Blood Cells of Alzheimer's Disease and Lewy Body Dementia Patients.
Daniele S; Baldacci F; Piccarducci R; Palermo G; Giampietri L; Manca ML; Pietrobono D; Frosini D; Nicoletti V; Tognoni G; Giorgi FS; Lo Gerfo A; Petrozzi L; Cavallini C; Franzoni F; Ceravolo R; Siciliano G; Trincavelli ML; Martini C; Bonuccelli U
J Alzheimers Dis; 2021; 80(2):885-893. PubMed ID: 33579836
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.
Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O
Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
